Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: A series of four cases

Journal of Clinical Apheresis

Volumn 27, Issue 4, 2012, Pages 215-220

  Košt́ál, Milan ^a   Bláha, Milan ^a   Lánská, Miriam ^a   Košt́álová, Marie ^a   Bláha, Vladimír ^b   Štepánová, Eva ^a   Malý, Jaroslav ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Lyell's syndrome; plasmapheresis; Steven Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CLEMASTINE FUMARATE; HUMAN ALBUMIN; HYDROCORTISONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; RINGER LACTATE SOLUTION;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL; BODY SURFACE; BULLOUS DERMATITIS; CASE REPORT; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE SEVERITY; EPITHELIUM; ERYTHEMA; FEMALE; FEVER; HOME CARE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; INTENSIVE CARE UNIT; LEUKOCYTOSIS; MALE; PLASMA VOLUME; PLASMAPHERESIS; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA; SEPSIS; SINGLE DRUG DOSE; SKIN DEFECT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT FAILURE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PLASMAPHERESIS; SKIN; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME;

EID: 84864674242     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21213     Document Type: Article

References (25)

1. Lyell A,. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68: 355-361.
2. Pereira FA, Mudgil AV, Rosmarin DM,. Toxic epidermal necrolysis. J Am Acad Dermatol 2007; 56: 181-200. (Pubitemid 46074234)
3. De Araujo E, Dessirier V, Laprée G, Valeyrie-Allanore L, Ortonne N, Stathopoulos EN, Bagot M, Bensussan A, Mockenhaupt M, Roujeau JC, Tsapis A,. Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol 2011; 20: 107-112.
4. Worswick S, Cotliar J,. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options. Dermat Ther 2011; 24: 207-218.
5. Carrozzo M, Togliatto M, Gandolfo S,. Erythema multiforme. A heterogeneous pathologic phenotype. Minerva Stomatol 1999; 48: 217-226.
6. Mukasa Y, Craven N,. Management of toxic epidermal necrolysis and related syndromes. Postgrad Med J 2008; 84: 60-65. (Pubitemid 351427571)
7. Yamada H, Takamori K,. Status of plasmapheresis for the treatment of toxic epidermal necrolysis in Japan. Ther Apher Dial 2008; 12: 355-359.
8. Szczeklik W, Nowak I, Seczynska B, Sega A, Krolikowski W, Musial J,. Beneficial therapeutic effect of plasmapheresis after unsuccessful treatment with corticosteroids in two patients with severe toxic epidermal necrolysis. Ther Apher Dial 2010; 14: 354-357.
9. Klein PA,. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Available at:.
10. Bastuji-Garin S, Fouchard N, Bertocchi M, V Roujeau JC, Revuz J, Wolkenstein P,. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-153. (Pubitemid 30637181)
11. Fromowitz JS, Ramos-Caro FA, Flowers FP,. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome. University of Florida. Int J Dermatol 2007; 46: 1092-1094. (Pubitemid 47506383)
12. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson CH, Revuz J,. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-1589. (Pubitemid 28515243)
13. Yang Y, Xu J, Li F, Ward KE, Archambault R, Mersfelder TL,. Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: a review of the literature. Am J Health Syst Pharm 2010; 67: 206-213.
14. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M,. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40. (Pubitemid 350298143)
15. Lissia M, Mulas P, Bulla A, Rubino C,. Toxic epidermal necrolysis (Lyell's disease). Burns 2010; 36: 152-163.
16. Yip LW, Thong BY, Tan AW, Khin LW, Chng HH, Heng WJ,. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye (Lond) 2005; 19: 846-853. (Pubitemid 41195136)
17. Bachot N, Revuz J, Roujeau JC,. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003; 139: 33-36. (Pubitemid 36091571)
18. Yang Y, Xu J, Li F, Zhu X,. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. Int J Dermatol 2009; 48: 1122-1128.
19. Engelhardt SL, Schurr MJ, Helgerson RB,. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil 1997; 18: 520-524. (Pubitemid 27508548)
20. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH,. Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25: 83-177.
21. Lyell A,. A review of toxic epidermal necrolysis in Britain. Br J Dermatol 1967; 79: 662-671.
22. Bláha M, Cermanová M, Bláha V, Blažek M, Malý J, Široký O, Solichová D, Filip S, Rehácek V,. Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia. Ther Apher Dial 2007; 11: 9-15.
23. Bláha M,. Extracorporeal LDL-cholesterol elimination in the treatment of severe familial hypercholesterolemia. Acta Medica (Hradec Králové) 2003; 46: 3-7.
24. Stegmayr B, Ptak J, Nilsson T, Blaha M, Berlin G, Griskevicius A, Audzijoniene J, Ramlow W, Centoni P, Newman E, Tomaz J, Witt V, Stojkovski L, Elot S, Prophet H,. Report of World Apheresis Association registry data until June 2010. Trans Apher Sci 2010; 43: S9-S10.
25. Lánská M, Vališ M, Bláha M, Strnadová B, Malý J,. Therapeutic plasmapheresis in neurologic diseases (in Czech). Aktual Nefrol 2010; 16: 44-50.